אסיף מאגר המחקר החקלאי

Tumorigenicity and immunogenicity in a murine model of B-cell leukemia/lymphoma (BCL1)

Year:

1998

Source of publication :

Authors :

Volume :

22

Co-Authors:

Morecki, S., Dept. of Bone Marrow Transplantation, Cancer Immunobiol. Res. Laboratory, Hadassah University Hospital, Jerusalem 91120, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Cancer Immunobiol. Res. Laboratory, Hadassah University Hospital, Jerusalem 91120, Israel
Zakay-Rones, Z., Department of Virology, Hebrew Univ. Hadassah Med. School, Jerusalem 91120, Israel
Schlesinger, M., Department of Virology, Hebrew Univ. Hadassah Med. School, Jerusalem 91120, Israel
Lubina-Salomon, A., Dept. of Bone Marrow Transplantation, Cancer Immunobiol. Res. Laboratory, Hadassah University Hospital, Jerusalem 91120, Israel
Pugatsch, T., Dept. of Bone Marrow Transplantation, Cancer Immunobiol. Res. Laboratory, Hadassah University Hospital, Jerusalem 91120, Israel
Moshel, Y., Dept. of Bone Marrow Transplantation, Cancer Immunobiol. Res. Laboratory, Hadassah University Hospital, Jerusalem 91120, Israel
Slavin, S., Dept. of Bone Marrow Transplantation, Cancer Immunobiol. Res. Laboratory, Hadassah University Hospital, Jerusalem 91120, Israel

Facilitators :

Link :

Abstract:

Multiple injections of intact irradiated BCL1 cells, a murine B-cell leukemia/lymphoma can trigger a dose-dependent anti-tumor immune response in naive syngeneic mice. The ability to induce anti-BCL1 immunity and the effect of various cell-modifications on BCL1 tumorigenicity and immunogenicity was evaluated. Newcastle disease virus (NDV) infection or transfer of cytokine genes by both retroviral and Adeno 5 vectors affect neither tumorigenicity nor immunogenicity of BCL1 cells given as a non-immunogenic cell-dose. New ways will have to be developed to elicit a reliable and reproducible anti-tumor effect in spontaneously arising and non-immunogenic hematological malignancies.

Note:

Related Files :

תוכן קשור

More details

You may also be interested in